Phase 3 study assessing the efficacy of adding al3818 (catequentinib dihydrochloride, anlotinib hydrochloride) to chemotherapies in subjects with platimum resistant and refractory ovarian carcinoma
| dc.contributor.author | Miller, D. | |
| dc.contributor.author | Zhou, Q. | |
| dc.contributor.author | Banerjee, S. | |
| dc.contributor.author | Clamp, Andrew R | |
| dc.contributor.author | Qu, P. | |
| dc.contributor.author | Huang, M. | |
| dc.contributor.author | Nevadunsky, N. | |
| dc.contributor.author | Konecny, G. | |
| dc.date.accessioned | 2023-03-22T10:52:43Z | |
| dc.date.available | 2023-03-22T10:52:43Z | |
| dc.date.issued | 2022 | en |
| dc.identifier.citation | Miller D, Zhou Q, Banerjee S, Clamp A, Qu P, Huang M, et al. Phase 3 Study Assessing the Efficacy of Adding Al3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to Chemotherapies in Subjects with Platimum Resistant and Refractory Ovarian Carcinoma. International Journal of Gynecological Cancer. 2022 Dec;32:A240-A. PubMed PMID: WOS:000899252300500. | en |
| dc.identifier.doi | 10.1136/ijgc-2022-igcs.544 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/626150 | |
| dc.language.iso | en | en |
| dc.relation.url | https://dx.doi.org/10.1136/ijgc-2022-igcs.544 | en |
| dc.title | Phase 3 study assessing the efficacy of adding al3818 (catequentinib dihydrochloride, anlotinib hydrochloride) to chemotherapies in subjects with platimum resistant and refractory ovarian carcinoma | en |
| dc.type | Meetings and Proceedings | en |
| dc.contributor.department | University of Texas Southwestern Medical Center, Gynecologic Oncology, Dallas, USA; | en |
| dc.identifier.journal | International Journal of Gynecological Cancer | en |
| dc.description.note | en] | |
| refterms.dateFOA | 2023-03-22T11:00:18Z |
Files in this item
Name:
MillerD.pdf
Size:
52.41Kb
Format:
PDF
Description:
Identified with Open Access button